4
Indication details
- Control Arm
- Cisplatin or carboplatin/5-FU/cetuximab
- FDA Therapeutic Indication
- As monotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1
- Tumour Type
-
Head and neck cancer
- Tumour Sub-type
- Squamous cell
- Tumour Stage
- Recurrent or metastatic
- Tumour Sub-Group
- CPS PD-L1 expression ≥1
- Trial Name
- KEYNOTE-048
- NCT Number
- NCT02358031
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approval June 2019
- EMA Approval
- EMA (CHMP) October 2019 EC decision December 2019
Primary Outcome(s)
- Primary Outcome(s)
- PFS/OS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- OS Control
- 10.4 months 2-year OS: 17.7%
- OS Gain
- 1.9 months 2-year OS gain: 11.2%
- OS HR
- 0.74 (0.61-0.89)
Adjustments
- QoL Comment
-
No QoL benefit
- Toxicity Comment
-
Toxicity was reduced for pembro vs control in the whole population. No information is provided for the cohorts of interest. Thus, no upgrade should be implemented
Score (after adjustments)
- Preliminary non-curative score
-
4
- Non-curative score
-
4
- Comment
-
Three-arm trial comparing chemotherapy plus cetuximab versus chemotherapy plus pembrolizumab versus pembrolizumab monotherapy.
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 195
- Scorecard version
- 1
- Issue date
- 17.07.2020
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.